These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

343 related items for PubMed ID: 30121827

  • 1. Efficacy and Safety of Secukinumab 150 mg with and Without Loading Regimen in Ankylosing Spondylitis: 104-week Results from MEASURE 4 Study.
    Kivitz AJ, Wagner U, Dokoupilova E, Supronik J, Martin R, Talloczy Z, Richards HB, Porter B.
    Rheumatol Ther; 2018 Dec; 5(2):447-462. PubMed ID: 30121827
    [Abstract] [Full Text] [Related]

  • 2. Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3.
    Pavelka K, Kivitz A, Dokoupilova E, Blanco R, Maradiaga M, Tahir H, Pricop L, Andersson M, Readie A, Porter B.
    Arthritis Res Ther; 2017 Dec 22; 19(1):285. PubMed ID: 29273067
    [Abstract] [Full Text] [Related]

  • 3. Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis.
    Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, Deodhar A, Porter B, Martin R, Andersson M, Mpofu S, Richards HB, MEASURE 1 Study Group, MEASURE 2 Study Group.
    N Engl J Med; 2015 Dec 24; 373(26):2534-48. PubMed ID: 26699169
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and Safety of Subcutaneous Secukinumab 150 mg with or Without Loading Regimen in Psoriatic Arthritis: Results from the FUTURE 4 Study.
    Kivitz AJ, Nash P, Tahir H, Everding A, Mann H, Kaszuba A, Pellet P, Widmer A, Pricop L, Abrams K.
    Rheumatol Ther; 2019 Sep 24; 6(3):393-407. PubMed ID: 31228101
    [Abstract] [Full Text] [Related]

  • 5. Secukinumab provided significant and sustained improvement in the signs and symptoms of ankylosing spondylitis: results from the 52-week, Phase III China-centric study, MEASURE 5.
    Huang F, Sun F, Wan WG, Wu LJ, Dong LL, Zhang X, Kim TH, Sengupta R, Šenolt L, Wang Y, Qiu HM, Porter B, Haemmerle S.
    Chin Med J (Engl); 2020 Nov 05; 133(21):2521-2531. PubMed ID: 32925287
    [Abstract] [Full Text] [Related]

  • 6. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial.
    Baeten D, Baraliakos X, Braun J, Sieper J, Emery P, van der Heijde D, McInnes I, van Laar JM, Landewé R, Wordsworth P, Wollenhaupt J, Kellner H, Paramarta J, Wei J, Brachat A, Bek S, Laurent D, Li Y, Wang YA, Bertolino AP, Gsteiger S, Wright AM, Hueber W.
    Lancet; 2013 Nov 23; 382(9906):1705-13. PubMed ID: 24035250
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of secukinumab in Asian patients with active ankylosing spondylitis: 52-week pooled results from two phase 3 studies.
    Wei JC, Baeten D, Sieper J, Deodhar A, Bhosekar V, Martin R, Porter B.
    Int J Rheum Dis; 2017 May 23; 20(5):589-596. PubMed ID: 28544533
    [Abstract] [Full Text] [Related]

  • 8. Secukinumab Demonstrates Sustained Efficacy and Safety in a Taiwanese Subpopulation With Active Ankylosing Spondylitis: Four-Year Results From a Phase 3 Study, MEASURE 1.
    Tseng JC, Wei JC, Deodhar A, Martin R, Porter B, McCreddin S, Talloczy Z.
    Front Immunol; 2020 May 23; 11():561748. PubMed ID: 33324394
    [Abstract] [Full Text] [Related]

  • 9. Secukinumab and Sustained Improvement in Signs and Symptoms of Patients With Active Ankylosing Spondylitis Through Two Years: Results From a Phase III Study.
    Marzo-Ortega H, Sieper J, Kivitz A, Blanco R, Cohen M, Martin R, Readie A, Richards HB, Porter B, Measure 2 Study Group.
    Arthritis Care Res (Hoboken); 2017 Jul 23; 69(7):1020-1029. PubMed ID: 28235249
    [Abstract] [Full Text] [Related]

  • 10. Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study.
    Baraliakos X, Braun J, Deodhar A, Poddubnyy D, Kivitz A, Tahir H, Van den Bosch F, Delicha EM, Talloczy Z, Fierlinger A.
    RMD Open; 2019 Jul 23; 5(2):e001005. PubMed ID: 31565244
    [Abstract] [Full Text] [Related]

  • 11. Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study.
    Braun J, Baraliakos X, Deodhar A, Baeten D, Sieper J, Emery P, Readie A, Martin R, Mpofu S, Richards HB, MEASURE 1 study group.
    Ann Rheum Dis; 2017 Jun 23; 76(6):1070-1077. PubMed ID: 27965257
    [Abstract] [Full Text] [Related]

  • 12. Secukinumab 150/300 mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 3-Year Results from the Phase 3 MEASURE 3 Study.
    Pavelka K, Kivitz AJ, Dokoupilova E, Blanco R, Maradiaga M, Tahir H, Wang Y, Porter BO, Stefanska A, Richards HB, Rohrer S, MEASURE 3 study group.
    ACR Open Rheumatol; 2020 Feb 23; 2(2):119-127. PubMed ID: 31957970
    [Abstract] [Full Text] [Related]

  • 13. Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study.
    Braun J, Baraliakos X, Deodhar A, Poddubnyy D, Emery P, Delicha EM, Talloczy Z, Porter B.
    Rheumatology (Oxford); 2019 May 01; 58(5):859-868. PubMed ID: 30590813
    [Abstract] [Full Text] [Related]

  • 14. Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from the phase III trial, MEASURE 2.
    Marzo-Ortega H, Sieper J, Kivitz A, Blanco R, Cohen M, Delicha EM, Rohrer S, Richards H.
    RMD Open; 2017 May 01; 3(2):e000592. PubMed ID: 29435364
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of secukinumab in Japanese patients with active ankylosing spondylitis: 24-week results from an open-label phase 3 study (MEASURE 2-J).
    Kishimoto M, Taniguchi A, Fujishige A, Kaneko S, Haemmerle S, Porter BO, Kobayashi S.
    Mod Rheumatol; 2020 Jan 01; 30(1):132-140. PubMed ID: 30334633
    [Abstract] [Full Text] [Related]

  • 16. Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study.
    Sieper J, Deodhar A, Marzo-Ortega H, Aelion JA, Blanco R, Jui-Cheng T, Andersson M, Porter B, Richards HB, MEASURE 2 Study Group.
    Ann Rheum Dis; 2017 Mar 01; 76(3):571-592. PubMed ID: 27582421
    [Abstract] [Full Text] [Related]

  • 17. Long-term effects of interleukin-17A inhibition with secukinumab in active ankylosing spondylitis: 3-year efficacy and safety results from an extension of the Phase 3 MEASURE 1 trial.
    Baraliakos X, Kivitz AJ, Deodhar AA, Braun J, Wei JC, Delicha EM, Talloczy Z, Porter B, MEASURE 1 Study Group.
    Clin Exp Rheumatol; 2018 Mar 01; 36(1):50-55. PubMed ID: 28516874
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and Safety of Subcutaneous and Intravenous Loading Dose Regimens of Secukinumab in Patients with Active Rheumatoid Arthritis: Results from a Randomized Phase II Study.
    Tlustochowicz W, Rahman P, Seriolo B, Krammer G, Porter B, Widmer A, Richards HB.
    J Rheumatol; 2016 Mar 01; 43(3):495-503. PubMed ID: 26834211
    [Abstract] [Full Text] [Related]

  • 19. Long-term effects of secukinumab on MRI findings in relation to clinical efficacy in subjects with active ankylosing spondylitis: an observational study.
    Baraliakos X, Borah B, Braun J, Baeten D, Laurent D, Sieper J, Emery P, McInnes IB, van Laar JM, Wordsworth P, Wollenhaupt J, Kellner H, Colin L, Vandenhende F, Radford K, Hueber W.
    Ann Rheum Dis; 2016 Feb 01; 75(2):408-12. PubMed ID: 26248638
    [Abstract] [Full Text] [Related]

  • 20. Secukinumab in Active Rheumatoid Arthritis after Anti-TNFα Therapy: A Randomized, Double-Blind Placebo-Controlled Phase 3 Study.
    Tahir H, Deodhar A, Genovese M, Takeuchi T, Aelion J, Van den Bosch F, Haemmerle S, Richards HB.
    Rheumatol Ther; 2017 Dec 01; 4(2):475-488. PubMed ID: 29138986
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.